The 5-HT1A receptor family (5-HT1AR) is an attractive target for the pharmacotherapy of pathologies associated with dysfunctional serotonergic neurotransmission, including anxiety, depression, Parkinson’s disease, pain, and schizophrenia. This evidence concerns the gene HTR1A and depressive disorder.